prednisone delayed-release tablet / Generic mfg. - LARVOL DELTA

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2027 ➔ Sep 2028 | Trial primary completion date: Sep 2027 ➔ Sep 2028

Trial completion date • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Secondary Central Nervous System Lymphoma • T Cell Histiocyte Rich Large B Cell Lymphoma • BCL2 • BCL6 • IRF4 • MME

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone (clinicaltrials.gov) - P2 | N=32 | Active, not recruiting | Sponsor: Ivan de Kouchkovsky, MD | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2027 ➔ Apr 2031 | Trial primary completion date: Sep 2027 ➔ Aug 2026

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1 | N=46 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (clinicaltrials.gov) - P2 | N=202 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT) (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1 trial • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Otorhinolaryngology • Solid Tumor

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis (clinicaltrials.gov) - P4 | N=700 | Recruiting | Sponsor: Berinstein, Jeffrey | N=162 ➔ 700 | Trial completion date: May 2026 ➔ Nov 2027 | Trial primary completion date: May 2026 ➔ Nov 2027

Enrollment change • Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=17 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2027 ➔ Oct 2028

Trial completion date • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology

P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jul 2026 ➔ Apr 2027

Trial completion date • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK • TNFRSF8

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov) - P2 | N=8 | Terminated | Sponsor: Mayo Clinic | Active, not recruiting ➔ Terminated; Sponsor decided to close due to slow accrual and lack of efficacy

Trial termination • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • SPOP

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma (clinicaltrials.gov) - P2/3 | N=271 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P2/3 trial • B Cell Lymphoma • Burkitt Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6

CARiBOU: Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) - P2 | N=41 | Active, not recruiting | Sponsor: Academic and Community Cancer Research United | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2024 ➔ Aug 2025

Enrollment closed • Trial primary completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • Transplantation

SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=53 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2027 ➔ Jun 2027

Trial completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • ABL1 • BCR • CD4 • CSF1R • FGFR • PDGFRA • PDGFRB

CONTRAC-2: Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=22 | Not yet recruiting | Sponsor: Washington University School of Medicine

New P2 trial • Non-melanoma Skin Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Jonsson Comprehensive Cancer Center

New P1 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD20

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Recruiting

Enrollment open • IO biomarker • Adult T-Cell Leukemia-Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD2 • CD4

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P1 | N=38 | Active, not recruiting | Sponsor: Yazeed Sawalha | Trial primary completion date: Dec 2026 ➔ Jun 2026 | Suspended ➔ Active, not recruiting

Enrollment closed • Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P1/2 | N=33 | Active, not recruiting | Sponsor: University of Washington | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2027 ➔ Jan 2027

Enrollment closed • Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: OHSU Knight Cancer Institute | N=30 ➔ 40

Enrollment change • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Jun 2026 ➔ Jun 2028

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

UCDCC#303: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: University of California, Davis | Trial primary completion date: Feb 2026 ➔ Oct 2026

Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD4

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial (clinicaltrials.gov) - P2 | N=202 | Not yet recruiting | Sponsor: Mayo Clinic

New P2 trial • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (clinicaltrials.gov) - P1/2 | N=35 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Recruiting

Enrollment open • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Otorhinolaryngology • Solid Tumor

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study (clinicaltrials.gov) - P2 | N=43 | Not yet recruiting | Sponsor: AIDS Malignancy Consortium

New P2 trial • Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4

AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P1 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Human Immunodeficiency Virus • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20 • CD4

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial (clinicaltrials.gov) - P3 | N=102 | Not yet recruiting | Sponsor: SWOG Cancer Research Network | Initiation date: May 2026 ➔ Aug 2026

Trial initiation date • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma